Harrow Earnings Reports

Harrow delivered a solid third quarter with a return to positive GAAP net income and significant growth in adjusted EBITDA, driven by strong performance of VEVYE® and IHEEZO®.

Harrow delivered a strong second quarter in 2025, with total revenues increasing by 30% year-over-year to $63.7 million and achieving a GAAP net income of $5.0 million, a significant improvement from a loss in the prior-year period. The company's key products, VEVYE and IHEEZO, showed strong commercial momentum, contributing to the positive financial performance.

Harrow reported a 38% increase in first-quarter 2025 revenue to $47.8 million compared to the prior year, driven by strong performance in key products like VEVYE. Despite a GAAP net loss of $17.8 million and negative Adjusted EBITDA of $2.0 million, the company achieved a record high cash flow from operations of $19.7 million and ended the quarter with $66.7 million in cash.

Harrow delivered a record $66.8 million in revenue for Q4 2024, marking an 84% increase over the prior-year period. The company reported $6.78 million in GAAP net income, with EPS of $0.19 basic and $0.24 diluted. Adjusted EBITDA reached $22.5 million, highlighting the company's profitability and operational leverage.

Harrow reported a 44% year-over-year revenue growth in Q3 2024. The company expects a record-breaking finish to a transformative year, with strong performance in the fourth quarter.

Harrow announced strong second quarter results, with revenues increasing by 46% compared to the same quarter last year and 42% over the previous quarter. The growth was driven by exceptional performance across all business segments.

Harrow reported first quarter results, highlighting progress in key operational initiatives including building a dry eye disease franchise, expanding the retina franchise, and stabilizing ImprimisRx and Anterior Segment Products.

Harrow announced its fourth quarter and year-end 2023 financial results, highlighting the company's transformation and growth in the ophthalmic pharmaceuticals market. The company launched products and began generating cash from IHEEZO, VEVYE, and TRIESENCE.

Harrow announced record revenues for Q3 2023, a 50% increase year-over-year, driven by strong performance from branded pharmaceutical products, especially IHEEZO. However, the quarter had mixed operational results, with some areas underperforming. The company has adjusted its 2023 financial guidance to revenues of $129 million to $136 million and Adjusted EBITDA of $36 million to $41 million.

Harrow announced its second quarter 2023 financial results, showcasing an improved product portfolio and progress toward achieving financial goals. The company's CEO highlighted the significant improvements in the balance sheet and the comprehensive ophthalmic pharmaceutical offerings in the U.S. market.

Harrow reported record revenues of $26.1 million for Q1 2023, a 28% increase over the previous quarter. The company reaffirms its 2023 revenue guidance of $135 million to $143 million and adjusted EBITDA of $44 million to $50 million.

Harrow announced its Q4 and year-end results, highlighting a transformational year with the FDA approval of IHEEZO™ and the expansion of their product portfolio.

Harrow announced its Q3 2022 results, marking an inflection point with FDA approval for IHEEZO, launch of Fortisite, and the sale of its non-ophthalmology compounded product line, focusing the company entirely on the U.S. ophthalmic pharmaceutical market.

Harrow Health announced strong financial and operational performance for Q2 2022, marking the eighth consecutive quarter of record results in key metrics. The company is focused on expanding its eyecare platform and integrating FDA-approved branded pharmaceutical products.

Harrow Health reported a strong start to 2022, marking its seventh consecutive quarter of record financial results. The company saw a 43% increase in year-over-year revenues and a nearly 10% increase from the sequential quarter.

Harrow Health reported record revenues for the fourth quarter of 2021, marking the sixth consecutive quarter of record performance. The company also achieved a gross margin of 75% during the quarter.

Harrow Health reported a fifth consecutive quarter of strong top-line revenue growth for Q3 2021. The company also achieved record levels in other key financial and operational metrics.

Harrow Health reported its best financial quarter in company history for Q2 2021, including new records in revenues, cash flow from operations, revenue per shipping day, and units shipped.

Harrow Health reported its best financial quarter in history for Q1 2021, with a 25% increase in product units distributed compared to the prior-year quarter and a 39% increase in commercial sales under the DEXYCU contract compared to Q4 2020.

Harrow Health reported a strong fourth quarter in 2020, with a 16% increase in total revenues and a significant rise in operating income. The company's financial performance reflected a continuation of the momentum seen in the previous quarter.

Harrow Health reported record revenues, gross margins, and adjusted EBITDA in Q3 2020. The CEO expressed optimism about the revenue trend transitioning from V-shaped to checkmark-shaped into 2021.

Harrow Health reported its results for the second quarter of 2020, noting that the impact from COVID-19 was substantial for a limited period, but the segments of the economy that are most relevant to their success recovered rapidly and are now at near-normal levels.

Harrow Health reported its first quarter 2020 results, with management expressing excitement about the ImprimisRx team's role in providing for physician customers and improving health outcomes as the economy reopens.

Harrow Health reported Q4 2019 results, highlighting strong gross margin performance and record-high adjusted EBITDA and cash flow from operations. The company does not anticipate disruptions from COVID-19 and believes it has ample supplies.